Summary

Report Scope
The report provides detailed information on monoclonal antibodies in oncology. This report analyzes the market trends and includes global revenue ($ million) for the base year 2024, estimated data for 2025, and forecast data from 2025 through 2030. The report highlights the current and future market potential of monoclonal antibodies in oncology and provides a detailed analysis of the competitive environment. It includes regulatory scenarios, drivers, restraints and opportunities, as well as market projections for 2030 and the market share for key companies. The market scope in this report is segmented by type, cancer type and region. By type, the market is segmented into humanized, human and chimeric. The cancer type segment is characterized into lung cancer, breast cancer, colorectal cancer, lymphoma, leukemia, melanoma, multiple myeloma and other cancers. The region covered in this study includes North America, Europe, Asia-Pacific, the Middle East and Africa (MEA) and South America. The regional segment provides a detailed analysis of major countries, including the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia and India. The report aims to: - Analyze types of monoclonal antibodies in oncology.
- Analyze global market size and segmentation.
- Understand market constraints and drivers.
- Provide detailed market forecasts through 2030.
- Assess market shares, competitiveness and industry structure.
- Identify potential long-term impacts on the market for monoclonal antibodies in oncology.

Report Includes
- 91 data tables and 59 additional tables
- In-depth analysis of the global markets for monoclonal antibodies (mAbs) for oncology
- Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
- Estimates of the current market size and revenue prospects for the global market, along with a corresponding market share analysis based on type, cancer type and region
- Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, prospects and the impact of macroeconomic variables
- Highlights of promising new advancements in monoclonal antibody-based nanoparticle therapy in cancer treatment, the emergence of next-generation therapeutic inhibitors, their potential and mechanism of action
- Insights derived from Porterfs Five Forces model, as well as global supply chain analyses
- Review of the regulatory landscape featuring the U.S. premarket notifications and approvals with emphasis on recently approved products as well as products under development or in different stages of clinical trials
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- A relevant patent analysis, featuring key granted and published patents
- Analysis of the industry structure, including companiesf market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Co., Johnson & Johnson Services, AstraZeneca, and Amgen Inc.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview
Overview
Macroeconomic Factors Analysis
Impact of U.S. Tariffs on the Pharmaceutical Industry
Healthcare Expenditure
Aging Population
Geopolitical Risks, Trade Wars and Supply Chain Disruptions
Impact of Global Economic Growth (GDP) on the Pharmaceutical Sector
Porter’s Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential for New Entrants
Threat of Substitutes
Competitiveness in the Industry
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Acceleration in Cancer Rates
Unmet Treatment Need and the Role of Monoclonal Antibodies in Oncology
Increasing R&D Spending by Companies
Rise in Government Funding and Pharmaceutical R&D Spending
Market Restraints
High Cost of Monoclonal Antibodies
Loss of Exclusivity and Genericization
Shortage of Oncology Professionals
Market Opportunities
Potential of Monoclonal Antibodies in Oncology
Emerging Markets
Chapter 4 Regulatory Landscape
Overview
U.S.
Europe
Asia-Pacific
Chapter 5 Emerging Technologies, Clinical Trial Analysis and Patent Analysis
Overview
Artificial Intelligence (AI)
Immunotherapy and Cell Therapy
Emergent Biomarkers
Clinical Trial Analysis
Clinical Trials Analysis by Type of Study
Clinical Trials Analysis by Status
Clinical Trials Analysis by Phase
Key Takeaways
Patent Analysis
Key Takeaways
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Global Market for Monoclonal Antibodies in Oncology, by Type
Key Takeaways
Humanized
Human
Chimeric
Global Market for Monoclonal Antibodies in Oncology, by Cancer Type
Key Takeaways
Lung Cancer
Breast Cancer
Colorectal Cancer
Lymphoma
Leukemia
Melanoma
Multiple Myeloma
Other Cancers
Geographic Breakdown
Global Market for Monoclonal Antibodies in Oncology, by Region
Key Takeaways
North America
Europe
Asia-Pacific
South America
Middle East and Africa
Chapter 7 Competitive Intelligence
Key Takeaways
Competitive Landscape
Company Share Analysis
Chapter 8 Sustainability in the Global Market for Monoclonal Antibodies in Oncology: An ESG Perspective
Introduction to ESG
Sustainability in the Global Market for Monoclonal Antibodies in Oncology
ESG Perspective
Environmental Impact
Social Impact
Governance Impact
ESG Risk Ratings
Conclusion
Chapter 9 Appendix
Methodology
Abbreviations
Sources
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
GSK PLC
JAZZ PHARMACEUTICALS INC.
JOHNSON & JOHNSON
LILLY USA LLC.
MERCK & CO. INC.
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Emerging Companies/Market Disruptors

ページTOPに戻る

List of Tables/Graphs

List of Tables
Summary Table : Global Market for Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 1 : Current Health Expenditure, by Country, 2021–2023
Table 2 : National Cancer Institute Funding, by Mechanism, 2020–2024
Table 3 : Average Price of a Few Monoclonal Antibodies
Table 4 : Few Approved Biosimilars in the Market
Table 5 : Clinical Trials in Monoclonal Antibodies in Oncology, by Type of Study, as of September 2025
Table 6 : Clinical Trials in Monoclonal Antibodies in Oncology, by Status, as of September 2025
Table 7 : Clinical Trials in Monoclonal Antibodies in Oncology, by Phase, as of September 2025
Table 8 : List of Selected Monoclonal Antibodies Clinical Trials Studies
Table 9 : List of Selected Recent Patents Related to Monoclonal Antibodies, 2024 - 2025
Table 10 : Global Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 11 : Top Humanized mAbs in the Global Market for Monoclonal Antibodies in Oncology, 2023–2024
Table 12 : Global Market for Humanized Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 13 : Top Human mAbs in the Global Market for Monoclonal Antibodies in Oncology, 2023 - 2024
Table 14 : Global Market for Human Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 15 : Top Chimeric mAbs in the Global Market for Monoclonal Antibodies in Oncology, 2023 - 2024
Table 16 : Global Market for Chimeric Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 17 : Global Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 18 : Global Market for Lung Cancer in Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 19 : Global Market for Breast Cancer in Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 20 : Global Market for Colorectal Cancer in Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 21 : Global Market for Lymphoma in Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 22 : Global Market for Leukemia in Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 23 : Global Market for Melanoma in Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 24 : Global Market for Multiple Myeloma in Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 25 : Global Market for Other Cancers in Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 26 : Global Market for Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 27 : North American Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 28 : North American Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 29 : North American Market for Monoclonal Antibodies in Oncology, by Country, Through 2030
Table 30 : U.S. Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 31 : U.S. Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 32 : Canadian Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 33 : Canadian Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 34 : Mexican Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 35 : Mexican Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 36 : European Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 37 : European Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 38 : European Market for Monoclonal Antibodies in Oncology, by Country, Through 2030
Table 39 : German Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 40 : German Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 41 : U.K. Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 42 : U.K. Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 43 : French Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 44 : French Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 45 : Italian Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 46 : Italian Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 47 : Spanish Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 48 : Spanish Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 49 : Rest of Europe Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 50 : Rest of Europe Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 51 : Cancer Cases in Asia-Pacific, by Sub-Region, 2022
Table 52 : Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 53 : Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 54 : Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Country, Through 2030
Table 55 : Chinese Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 56 : Chinese Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 57 : Japanese Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 58 : Japanese Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 59 : Indian Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 60 : Indian Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 61 : South Korean Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 62 : South Korean Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 63 : Australian Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 64 : Australian Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 65 : Rest of Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 66 : Rest of Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 67 : Cancer Cases in Selected South American Countries, 2022
Table 68 : South American Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 69 : South American Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 70 : South American Market for Monoclonal Antibodies in Oncology, by Country, Through 2030
Table 71 : Brazilian Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 72 : Brazilian Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 73 : Argentinian Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 74 : Argentinian Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 75 : Rest of South America Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 76 : Rest of South America Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 77 : MEA Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 78 : MEA Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 79 : MEA Market for Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 80 : Middle East Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 81 : Middle East Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 82 : Approved mAbs in African Countries
Table 83 : African Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 84 : African Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 85 : Key Strategic Initiatives in Global Market for Monoclonal Antibodies in Oncology, 2024 - 2025
Table 86 : Key Focus Areas in ESG Metrics
Table 87 : ESG Rankings for Leading Companies in Monoclonal Antibodies in Oncology, 2025*
Table 88 : Abbreviations Used in this Report
Table 89 : Report Sources
Table 90 : AbbVie Inc.: Company Snapshot
Table 91 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 92 : AbbVie Inc.: Product Portfolio
Table 93 : AbbVie Inc.: News/Key Developments, 2023–2025
Table 94 : Amgen Inc.: Company Snapshot
Table 95 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 96 : Amgen Inc.: Product Portfolio
Table 97 : Amgen Inc.: News/Key Developments, 2022–2025
Table 98 : AstraZeneca: Company Snapshot
Table 99 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 100 : AstraZeneca: Product Portfolio
Table 101 : AstraZeneca: News/Recent Developments, 2023–2025
Table 102 : Bristol-Myers Squibb Co.: Company Snapshot
Table 103 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 104 : Bristol-Myers Squibb Co.: Product Portfolio
Table 105 : Bristol-Myers Squibb Co.: News/Key Developments, 2023–2025
Table 106 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 107 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 108 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 109 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022–2025
Table 110 : Gilead Sciences Inc.: Company Snapshot
Table 111 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 112 : Gilead Sciences Inc.: Product Portfolio
Table 113 : Gilead Sciences Inc.: News/Key Developments, 2023-2024
Table 114 : GSK plc: Company Snapshot
Table 115 : GSK plc: Financial Performance, FY 2023 and 2024
Table 116 : GSK plc: Product Portfolio
Table 117 : GSK plc: News/Key Developments, 2023–2025
Table 118 : Jazz Pharmaceuticals Inc.: Company Snapshot
Table 119 : Jazz Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 120 : Jazz Pharmaceuticals Inc.: Product Portfolio
Table 121 : Jazz Pharmaceuticals Inc.: News/Key Developments, 2024-2025
Table 122 : Johnson & Johnson: Company Snapshot
Table 123 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
Table 124 : Johnson & Johnson: Product Portfolio
Table 125 : Johnson & Johnson.: News/Key Developments, 2022–2025
Table 126 : Lilly USA LLC.: Company Snapshot
Table 127 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
Table 128 : Lilly USA LLC.: Product Portfolio
Table 129 : Lilly USA LLC.: News/Key Development, 2022-2023
Table 130 : Merck & Co. Inc.: Company Snapshot
Table 131 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 132 : Merck & Co. Inc.: Product Portfolio
Table 133 : Merck & Co. Inc.: News/Key Developments, 2022–2025
Table 134 : Pfizer Inc.: Company Snapshot
Table 135 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 136 : Pfizer Inc.: Product Portfolio
Table 137 : Pfizer Inc.: News/Key Developments, 2023–2025
Table 138 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 139 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 140 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 141 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022–2025
Table 142 : Sanofi: Company Snapshot
Table 143 : Sanofi: Financial Performance, FY 2023 and 2024
Table 144 : Sanofi: Product Portfolio
Table 145 : Sanofi: News/Key Developments, 2022–2025
Table 146 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 147 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
Table 148 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 149 : A Few Emerging Companies in the Global Market for Monoclonal Antibodies in Oncology